Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0035 plus fulvestrant in HR+/HER2- PIK3CA-mutated advanced breast cancer after endocrine therapy failure
CTR20263305Phase 3Active
- Sponsor
- Jiayue Pharma
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JYP0035 in breast cancer, sponsored by Jiayue Pharma. Started Aug 2026; status: active.
02
Drugs
JYP0035
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263305.